Ward-Level Implementation and Post-Market Clinical Follow-up Study of ASISU Under Routine Clinical Practice (ASISU-PMCF)
Ward-Level Implementation and Observational Post-Market Clinical Follow-up Study of ASISU Under Routine Clinical Practice
This is a single-center, prospective, non-randomized post-market clinical follow-up study evaluating the implementation and clinical performance of ASISU during routine vaginal childbirth. ASISU is a Conformité Européenne (CE)-marked medical device, single-use medical device intended to provide perineal protection during the second stage of vaginal childbirth.
Approximately 280 nulliparous participants undergoing eligible vaginal birth at ≥37 weeks of gestation will be prospectively enrolled following ward-level implementation of ASISU.
ASISU will be used within its intended purpose and according to the Instructions for Use. Although ASISU is prospectively introduced at ward level as part of the study, use of ASISU in an individual birth remains subject to clinical judgment and is not mandated in every enrolled participant.
The study will evaluate implementation of ASISU in routine maternity care and clinical outcomes, including Grade 2 perineal tears. Outcomes following implementation will be compared descriptively with eligible historical pre-implementation routine-care data.
調査の概要
詳細な説明
ASISU is a CE-marked, single-use perineal protection device intended for use during the second stage of vaginal childbirth.
This study prospectively introduces ASISU at ward level within routine maternity care and evaluates its implementation and clinical performance. Midwives and relevant clinical staff will receive standardized training in use of ASISU before implementation.
Approximately 280 evaluable nulliparous participants undergoing eligible vaginal birth at ≥37 weeks of gestation will be prospectively enrolled. ASISU will be used within its intended purpose and according to the Instructions for Use.
Enrollment does not mandate application of ASISU in every individual birth. The responsible clinical staff retain discretion regarding whether ASISU is used according to the clinical circumstances, maternal preference and routine care.
Prospective clinical data will include ASISU use, non-use and discontinuation, reasons for non-use or discontinuation, episiotomy, perineal tear degree and type, maternal birthing position, maternal characteristics and infant birth weight.
The primary clinical outcome is the incidence of Grade 2 perineal tears. Outcomes following implementation will be compared descriptively with an eligible historical pre-implementation reference cohort derived from routine-care data, provided compatible outcome definitions and denominators are available.
Implementation outcomes include staff training and competency, integration into clinical workflow, successful device use, discontinuation and reasons for non-use.
The study does not involve randomization, blinding, use of ASISU outside its intended purpose, or additional invasive or burdensome clinical procedures.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Bushra Shahida, PhD
- 電話番号：+45 28262484
- メール：bushra@oasi.care
研究連絡先のバックアップ
- 名前：Lone Krebs, MD, PhD
- 電話番号：+45 3862 0705
- メール：lone.krebs@regionh.dk
研究場所
-
-
-
Hvidovre、デンマーク、2650
- Amager & Hvidovre Hospital
-
コンタクト：
- Lone Krebs, MD, PhD
- 電話番号：+45 3862 0705
- メール：lone.krebs@regionh.dk
-
コンタクト：
- Bushra Shahida, PhD
- メール：bushra@oasi.care
-
副調査官：
- Catharina Hein Hoffmann, MD
-
副調査官：
- Nanna Bjerg Pagh, Midwife
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Nulliparous participant
- Gestational age ≥37 completed weeks
- Eligible for vaginal birth
- Meets predefined study eligibility criteria -Written informed consent obtained before study-specific data collection -
Exclusion Criteria:
-
Birth requiring or proceeding to instrumental intervention for the primary efficacy endpoint. If such a conversion occurs after consent, the reason may still be summarized as an implementation interruption where recorded.
- Known perineal abnormality or complication incompatible with ASISU use or requiring surgical intervention during delivery.
- Births involving episiotomy.
- Planned caesarean section or intrapartum conversion to caesarean section for the clinical efficacy analysis.
- Birth in water.
- Genital warts (HPV/condylomata) affecting the perineal area.
- Perineal varices.
- Active genital herpes outbreak.
- Known hypersensitivity or intolerance to ASISU device materials or adhesive.
- For the prospective observational cohort: inability or unwillingness to provide valid informed consent excludes the individual from enrolment and from inclusion of her individual-level data in the study dataset. It does not, in itself, constitute a clinical contraindication to routine use of ASISU.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：ASISU Ward-Level Implementation
Participants enrolled following ward-level implementation of ASISU. ASISU is available for use during the second stage of vaginal childbirth according to its intended purpose and Instructions for Use. Application of ASISU in an individual birth remains subject to clinical judgment and is not mandated for every enrolled participant. |
ASISU is a CE-marked, single-use perineal protection device intended for use during the second stage of vaginal childbirth. The device is used according to its intended purpose and Instructions for Use. Following ward-level implementation, application in an individual birth is determined by the responsible clinical staff based on clinical circumstances and routine care and is not mandated in every enrolled participant. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Grade 2 Perineal Tears
時間枠：Immediately after vaginal childbirth
|
Proportion of eligible participants with a documented Grade 2 perineal tear. The numerator is the number of eligible participants with a documented Grade 2 perineal tear and the denominator is the number of eligible participants with known perineal tear grade. Grade 3 and Grade 4 perineal tears are not counted as Grade 2 events and will be reported separately and included in exploratory analyses of Grade ≥2 perineal tears. |
Immediately after vaginal childbirth
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Grade ≥2 perineal tears
時間枠：Immediately after vaginal childbirth
|
Proportion of eligible participants experiencing Grade 2, Grade 3 or Grade 4 perineal tears. |
Immediately after vaginal childbirth
|
|
Successful ASISU use
時間枠：During vaginal childbirth, assessed immediately after each delivery
|
Number and proportion of births in which ASISU use was attempted and successfully completed without device discontinuation. |
During vaginal childbirth, assessed immediately after each delivery
|
|
ASISU non-use
時間枠：Through completion of the 3-month implementation period
|
Number and proportion of enrolled eligible births in which ASISU was not used, including documented reasons for non-use. |
Through completion of the 3-month implementation period
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Lone Krebs, MD, PhD、Amager & Hvidovre Hospital
出版物と役立つリンク
一般刊行物
- Smith LA, Price N, Simonite V, Burns EE. Incidence of and risk factors for perineal trauma: a prospective observational study. BMC Pregnancy Childbirth. 2013 Mar 7;13:59. doi: 10.1186/1471-2393-13-59.
- Opondo C, Harrison S, Sanders J, Quigley MA, Alderdice F. The relationship between perineal trauma and postpartum psychological outcomes: a secondary analysis of a population-based survey. BMC Pregnancy Childbirth. 2023 Sep 6;23(1):639. doi: 10.1186/s12884-023-05950-6.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- ASISU-PMCF-HH-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
There is currently no plan to share individual participant data. Any future data sharing would be subject to applicable data protection requirements, participant confidentiality, and relevant institutional and ethical approvals.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。